Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer on October 31, 2026. There are 5 upcoming events on record.
Cash runway is approximately 30.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 31, 2026 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Trial Milestone | Phase 3 |
| December 14, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| May 30, 2027 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Trial Milestone | Phase 1 |
| December 31, 2027 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Trial Milestone | Phase 1 |
| December 15, 2028 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Trial Milestone | Phase 3 |
Track OLMA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open OLMA in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.